Editor's note

This ExpertREACT article was originally published on 18 February 2010. Financial results and market positions described reflect the state of knowledge at that date.

The $20bn barrier broken

According to VacZine Analytics' calculations, the top five vaccine companies sold approximately $20.7bn in vaccines in 2009 - a 10% increase on 2008 in non-comparable terms, and approximately 17% on a comparable exchange-rate basis. The pandemic H1N1 outbreak, which emerged in April 2009, was the single largest contributor to the year's remarkable performance. The top five players, supplemented by contributions from Medimmune (AstraZeneca), Baxter and CSL, collectively shipped around 320 million H1N1 monovalent doses to the end of 2009, adding approximately $3.6bn in incremental industry revenue. VacZine Analytics estimated the global vaccine industry including local producers could be approaching the $25bn mark.

Novartis Vaccines (excluding diagnostics) recorded the fastest company growth in 2009 at approximately +53%, driven by an additional $1bn in H1N1 sales booked in Q4. By end 2009 Novartis had recognised approximately $2.2bn in cumulative H1N1 sales. GSK Biologicals had the highest dollar sales, while Merck & Co recorded a notable decline from $4,206m in 2008 to $3,632m in 2009 - partly reflecting the continued maturation and growing competition for Gardasil and Prevnar products. Both GSK and Sanofi Pasteur guided that H1N1 revenues would remain "significant" in 2010, suggesting the pandemic windfall would extend further into the forward year.

Top 5 vaccine sales FY 2009
$20.7bn
H1N1 contributed approximately $3.6bn in incremental revenue; Novartis Vaccines grew fastest at +53% on 2008

Meningococcal ACWY launches ahead

Looking forward to 2010, VacZine Analytics highlighted expected product launches in the meningococcal ACWY space - including Wyeth's Menhibrix, Novartis' Menveo and Sanofi's expanded Menactra indications - as the most likely near-term industry growth drivers once the H1N1 windfall faded. The Pfizer-Wyeth merger, completed in 2009, had created a new combined entity with a strong pneumococcal franchise (PCV-13) and emerging meningococcal capability that would force existing players to accelerate their competitive positioning strategies.